OBJECTIVES: Treatment Satisfaction Questionnaire for Medication (TSQM) (score range 0-100) has been shown to be a reliable and valid instrument to measure patients’ satisfaction with their treatment for multiple sclerosis (MS). The 14-item TSQM Version1.4 provides scores across four domains: effectiveness, convenience, global satisfaction, and side effects. The abbreviated 9-item TQSM-9 excludes the side effects domain. Positive changes in score indicate improvement. We conducted a systematic review of clinical studies that reported MS patient satisfaction with their disease-modifying therapies (DMTs) using TSQM. METHODS: We systematically searched EMBASE, MEDLINE, BIOSIS Previews and Medmeme with pre-specified search terms from 2004 onwards for manuscripts and conference proceedings of prospective MS studies. The outcomes of interest included study type, change from baseline (CFB) in TSQM scores by DMT group, and differences in CFB in TSQM across treatment groups.  RESULTS: Six studies met all study criteria (3 single-arm observational or surveillance studies and 3 randomized studies). The DMTs studied included interferon beta-1b, glatiramer acetate, fingolimod, teriflunomide, and natalizumab. Two studies used TSQM Version1.4, while four used TSQM-9. Study length ranged from 12 weeks to 3 years. CFB at 6 months was the most commonly reported outcome. The CFB at 6 months on the effectiveness subscale ranged from 1.8 to 26.9, convenience subscale from 3.6 to 41.2, and global satisfaction subscale from 2.9 to 20.4. The CFB at 6 months was generally higher for natalizumab and fingolimod compared with injectable platform DMTs, although this finding may be confounded by the differences in study design and patient characteristics. CONCLUSIONS: Several MS studies have used the TSQM to measure patient satisfaction with DMTs. Comparisons across identified studies is challenging, as there is substantial heterogeneity with regards to version of TSQM used, study type and length, and type of analyses reported.